Mobile website
Archive > Volume 24 Issue 2 > 2017,24(2):151-157. DOI:10.3872/j.issn.1007-385X.2017.02.009 Prev Next
Clinical Research
Multiple antigen stimulating cellular therapy combined with transcatheter arterial chemoembolization on hepatocellular carcinoma
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To observe the clinical efficacy of MASCTTM (multiple antigen stimulating cellular therapy) combined with transcatheter arterial chemoembolization (TACE) on primary hepatocellular carcinoma (HCC). Methods：The clinical data of 66 HCC patients with TACE during August 2010 to March 2015 in the Department of Infectious Diseases (Center of Liver Disease) of Nanfang Hospital were retrospectively analyzed. The patients were divided into combination group (TACE+ MASCTTM treatment) (32 patients) and TACE group (34 patients). The progression-free survival (PFS) and overall survival (OS) were evaluated in the two groups as main outcome measures. Results:The six-month, 1-year, 2-year PFS rates were 68.8%, 37.5%, 25% in combination group and 50%, 11.8%, 2.9% in TACE group, respectively. The median PFS was 9.5 months in combination group compared with 5.5 months in TACE group（P＜0.01）. The six-month, 1-year, 2-year OS rates were 81.3%, 65.6%, 40.6% in combination group and 91.2%, 47.1%, 23.5% in TACE group, respectively. The median OS was 19.5 months in combination group compared with 10.5 months in TACE group (P<0.05). MASCTTM, portal vein invasion, pretreatment serum AFP level and ECOG performance status were the independent prognostic factors for PFS, while MASCTTM, portal vein invasion and pretreatment serum TBIL level were the independent prognostic factors for OS. Conclusion: MASCTTM combined with TACE could robustly improve the clinical efficacy, and obviously prolong the PFS and OS for HCC patients.
Keywords:
Project Supported:
Clc Number:
